CLLS earnings: next report 2026-08-11, real EPS beat/miss history, analyst consensus Buy, P/E -4.23. Updated 2026-07-23.
Cellectis (CLLS) Research Hub
Cellectis (CLLS) trades on NASDAQ, FR in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 3.1 USD (-0.96%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -4.23, market cap 0.29B. This hub links to the full technical, earnings and options research available for CLLS.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, FR |
| Last close | 3.1 USD (-0.96%) |
| 52-week range | 2.35 USD – 3.57 USD |
| Trend regime | Range |
| 14-day RSI | 62 (Bullish) |
| Trailing P/E | -4.23 |
| Market cap | 0.29B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-11 |
Available research for CLLS
Covered Call on CLLS: how it works, illustrative setup around the real 3.1 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on CLLS: how it works, illustrative setup around the real 3.1 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on CLLS: how it works, illustrative setup around the real 3.1 USD price, max profit/loss, breakeven and when to use it. Educational.
CLLS technical analysis: range, last 3.1 USD, RSI 62, 52w range 2.35 USD–3.57 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is CLLS in?
Cellectis (CLLS) is classified under Healthcare (Biotechnology), listed on NASDAQ, FR.
Is CLLS in an uptrend or downtrend?
As of 2026-09-11, CLLS is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is CLLS's trailing P/E ratio?
CLLS's trailing P/E is -4.23, with a market cap of 0.29B. See the earnings research page for full valuation detail.
When does CLLS next report earnings?
CLLS is next scheduled to report earnings on 2026-08-11, with a consensus EPS estimate of -0.263 USD.